KDR and breast carcinoma: Erlotinib, Vandetanib, Lapatinib, and Axitinib are FDA-approved drugs that affect protein tyrosine kinases, inhibit EGFR and VEGFR, and are used to treat cancers such as lung cancer, breast cancer, thyroid cancer, and melanoma50.